Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA hearing officer Karen Midthun rejects the Center for Drug Evaluation and Research's request to bar evidence on discussions over a new study of Avastin in first-line metastatic breast cancer.

You may also be interested in...



Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer

Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.

Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer

Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.

Avastin Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions

The decision on whether Avastin’s metastatic breast cancer indication should be retained may come down to three words – “magnitude of benefit.”

Related Content

Topics

UsernamePublicRestriction

Register

PS072298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel